Midatech Pharma Plc IPO-Jahr
Was ist das IPO-Jahr von Midatech Pharma Plc?
IPO-Jahr von Midatech Pharma Plc ist 2014
Was ist die Definition von IPO-Jahr?
Börsengang ist ein öffentliches Angebot, bei dem Aktien eines Unternehmens normalerweise an institutionelle Anleger verkauft werden, die ihrerseits erstmals an einer Wertpapierbörse an die breite Öffentlichkeit verkauft werden.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
IPO-Jahr von Unternehmen in Health Care Sektor auf LSE im Vergleich zu Midatech Pharma Plc
Was macht Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Unternehmen mit ipo-jahr ähnlich Midatech Pharma Plc
- Australian REIT Income Fund hat IPO-Jahr von 2013
- Brookfield Asset Management PRF SH CL A SE37 hat IPO-Jahr von 2013
- Modern Meat hat IPO-Jahr von 2013
- Blue Capital Reinsurance Ltd hat IPO-Jahr von 2013
- Siyata Mobile hat IPO-Jahr von 2013
- Mirati Therapeutics Inc hat IPO-Jahr von 2013
- Midatech Pharma Plc hat IPO-Jahr von 2014
- Glaukos hat IPO-Jahr von 2015
- UBS ETFs Public - MSCI ACWI SF UCITS ETF hat IPO-Jahr von 2015
- Acasta Enterprises hat IPO-Jahr von 2015
- Faron Pharmaceuticals Oy hat IPO-Jahr von 2015
- GreenPower Motor Co hat IPO-Jahr von 2015
- Sunrun Inc hat IPO-Jahr von 2015